

## *Connecticut's Opioid Settlements*

The United States is in the midst of a crisis on its streets and in its communities as overdoses, homelessness, and disorder reach record levels. Yet settlement proceeds secured by the State of Connecticut present an unprecedented opportunity for generational investment in treatment capacity for chronic substance abuse (CSA) and severe mental illness (SMI).

Connecticut is set to receive **more than \$600 million** (\$641,322,695.28) in opioid settlement funds—equal to nearly a fifth of the state's share of the monumental Tobacco Master Settlement Agreement.<sup>1</sup> With twenty separate settlements and payments spread out over decades, the funds are **at risk of being squandered** through ad-hoc allocations to **diffuse and disorganized efforts**.

The state must ensure that this opportunity for treatment investment is not underutilized. **Connecticut can make targeted investments in treatment capacity** that will honor those who **suffered** in the opioid crisis and **ensure accessible care** for decades to come.

Connecticut reserves 85 percent of funds (\$555,043,670.54) for use by the state in an abatement fund with the remainder allocated to subdivisions.<sup>1</sup> The state's share is administered by the 54-person Opioid Settlement Advisory Committee (OSAC).<sup>2</sup> OSAC has a specific list of "approved initiatives," including \$6 million for "harm reduction vending machines," \$1.3 million for syringe exchange programs, and \$60 million for supportive housing, among other initiatives.<sup>3</sup> Not only is this Committee far too large, the list of approved initiatives is proof the funds will not be spent on targeted priorities. **The state should amend its statute to abolish the Committee and vest control of the funds in the legislature.**

The state must rein in the misallocation of these funds and prioritize investments in comprehensive treatment networks. **Three priorities** (Certified Community Behavioral Health Clinics, secure psychiatric beds, and community SMI/CSA response) **will ensure these funds have the largest impact** on the state.

---

<sup>1</sup> With the exception of the McKinsey and Publicis settlements, in which the state controls 100 percent of funds.

## Certified Community Behavioral Health Clinics (CCBHCs)

CCBHCs, designed to ensure access to coordinated comprehensive behavioral health care, have stable funding and are supported by all recent presidential administrations. CCBHCs are a key response to the opioid crisis and can augment other services such as police crisis response teams, homelessness outreach and services, and outpatient psychiatric commitment services.

- **Solution: Fund the development and expansion of CCBHCs.**
  - o Expand the CCBHC footprint with an emphasis on a team-based approach to co-occurring disorders.
  - o Create a stepped approach to SMI/CSA treatment with services provided by the CCBHCs.
  - o Require CCBHCs to offer specific care pathways to meet the needs of individuals with co-occurring disorders.

## State Psychiatric Hospitals

Inpatient beds in secure facilities are critical for serving the highest-acuity psychiatric patients. Connecticut currently has only **7.9 state psychiatric beds** per 100,000 people available for civil (i.e., non-criminal) patients.<sup>45</sup> Treatment Advocacy Center recommends a rate of 30-60 beds per 100k. Even counting non-public secure psychiatric beds, Connecticut still falls short of the minimum.<sup>6</sup> Secure beds are a costly but necessary expenditure to protect patients with severe psychiatric disorders and the public at large.

- **Solution: Fund the expansion of civil psychiatric beds.**
  - o Invest in expanding state hospital capacity.
  - o Move forensic (criminal) commitments to a jail-based restoration facility.
  - o Apply for one of several Section 1115(a) waivers to expand Medicaid reimbursement for institutions for mental diseases (IMDs).

## Inpatient Stabilization Centers and Mobile Crisis Teams

Emergency departments (EDs) are supposed to be a last resort for times of true emergencies, but are increasingly used for all types of immediate-need medical care. This is especially true for low- to medium-acuity mental health crises. In order for CCBHCs and state psychiatric bed expansions to have the largest impact, there must be an immediate triage of low-acuity patients from higher-need patients, or else investments in these facilities will be drowned out, overburdened, and underutilized by those that need them most, just like emergency departments.

- **Solution: Fund community-based mental health response resources.**
  - Expand community-based recovery centers, including voluntary short-term respite housing, especially for young adults.
  - Leverage CCBHC resources to develop comprehensive mobile crisis response teams in conjunction with police crisis intervention teams (CIT).
  - Support integration of community resources with crisis networks such as the Lifeline to support those in need or provide guidance for concerned loved ones.

## CONNECTICUT

[Download all Connecticut opioid settlement documents](#)

[View settlement fund dashboard](#)

STATE-CONTROLLED FUNDS	ALL FUNDS	2025 EOY FUNDS RECEIVED - STATE	2025 EOY FUNDS RECEIVED - ALL	Av. Receipt (All Funds) / Yr (*20)
\$555,043,670.54	\$641,322,695.28	\$196,318,262.57	\$222,816,994.84	\$32,066,134.76

### **2021 National Opioid Settlement**

*Connecticut v. Distributors*

- [Final Consent Judgment](#)
  - Exhibit A “Distributor Settlement Agreement” [p. 13]
  - Allocation procedure, judgment ¶ 9 [p. 3]
  - Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Janssen Settlement Agreement” [p. 584]
- State of Connecticut v. McKesson Corporation, et al., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV22-6154105-S

*Connecticut v. Janssen*

- [Final Consent Judgment](#)
  - Exhibit A “Janssen Settlement Agreement” [p. 14]
  - Allocation procedure, judgment ¶ 8 [p. 3]
  - Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Janssen Settlement Agreement” [p. 523]
- State of Connecticut v. Janssen Pharmaceuticals, Inc., et al., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV22-6154110-S

### **2022 National Opioid Settlement**

*Connecticut v. CVS*

- [Final Stipulated Judgment](#) [p. 2]
  - [Exhibit A “agreement dated as of December 9 2022”](#)
- State of Connecticut v. CVS Pharmacy, Inc., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV24-6178093-S

*Connecticut v. Walgreens*

- [Final Stipulated Judgment \[p. 6\]](#)
  - Exhibit A “agreement dated as of December 9 2022” [p. 17]
  - Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Walgreens Settlement Agreement” [p. 842]
- State of Connecticut v. Walgreen Co., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV24-6178098-S

*Connecticut v. Walmart*

- [Final Stipulated Judgment \[p. 6\]](#)
  - Exhibit A “agreement dated as of November 14 2022” [p. 17]
  - Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Walmart Settlement Agreement” [p. 600]
- State of Connecticut v. Walmart Inc., Superior Court, District Court of Hartford at Hartford, Case No. HHD-CV24-6178096-S

*Connecticut v. Allergan*

- [Final Stipulated Judgment and Dismissal with Prejudice \[p. 6\]](#)
- Exhibit A “Allergan Public Global Opioid Settlement Agreement” [p. 17]
- Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Allergan Public Global Opioid Settlement Agreement” [p. 574]
- State of Connecticut v. Teva Pharmaceutical Industries, Ltd., et al., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV23-6177745-S

*Connecticut v. Teva*

- [Order Regarding Motion for Judgment in Accordance with Stipulation](#)
- [Final Stipulated Judgment and Dismissal with Prejudice](#)
  - Exhibit A “Teva Global Opioid Settlement Agreement” [p.12]
  - Exhibit B “Attorney General’s Release of Opioid-Related Claims Pursuant to the Teva Global Opioid Settlement Agreement” [p. 580]
- State of Connecticut v. Teva Pharmaceutical Industries, Ltd., et al., Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV23-6177745-S

**Other Coalition Opioid Settlements**

*Connecticut v. McKinsey*

- [Final Judgment](#)
- [McKinsey Allocation Amounts](#)
- State of Connecticut v. McKinsey & Company, Inc. United States, Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV21-6137935-S

*Connecticut v. Mallinckrodt*

- [NOAT II Agreement](#)
- [GPM Notice](#)
- [Notice of Abatement Distribution](#)

*Connecticut v. Publicis*

- [Final Stipulated Judgment](#)
- State of Connecticut v. Publicis Health, LLC, Superior Court, Judicial District of Hartford at Hartford, Case No. HHD-CV24-6179962-S

*Connecticut v. Endo*

- [Global Public Trust Agreement](#)
- [Notice of Abatement Distribution](#)

## **2025 National Settlements**

### *Connecticut v. Purdue*

- [missing documentation]
- State of Connecticut v. Purdue Pharma L.P., et al., Hartford State Superior Court, Case No. NO. X07 HHD-CV-19-6105325-S [unconfirmed]

### *Connecticut v. Mylan*

- [missing documentation]

### *Connecticut v. Hikma*

- [missing documentation]

### *Connecticut v. Amneal*

- [missing documentation]

### *Connecticut v. Apotex*

- [missing documentation]

### *Connecticut v. Indivior*

- [missing documentation]

### *Connecticut v. Sun Pharmaceuticals*

- [missing documentation]

### *Connecticut v. Alvogen*

- [missing documentation]

### *Connecticut v. Zydus*

- [missing documentation]

## **Independent Settlements**

---

<sup>1</sup> KFF. "Actual Tobacco Settlement Payments Received by the States (in millions)." Accessed 8 September 2025. <https://www.kff.org/health-costs/state-indicator/tobacco-settlement-payments>.

<sup>2</sup> Connecticut General Statutes § 17a-674c(a). [https://www.cga.ct.gov/current/pub/chap\\_319j.htm#sec\\_17a-674c](https://www.cga.ct.gov/current/pub/chap_319j.htm#sec_17a-674c).

<sup>3</sup> "Connecticut Opioid Settlement Fund Approved Initiatives." May 2025. <https://portal.ct.gov/-/media/dmhas/publications/osac/opioid-settlement-fund-approved-projects-one-pager-aug-25.pdf?rev=15754261c840468fb75587bb40825059&hash=3C0AB3A3B15E82B9E1B994225B791437>.

<sup>4</sup> Treatment Advocacy Center. "Connecticut Psychiatric Beds Report." 2023. <https://www.tac.org/wp-content/uploads/2023/10/Connecticutbedsinformation.pdf>.

<sup>5</sup> United States Census Bureau, "2023 American Community Survey – Total Population." [https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US\\$0400000](https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US$0400000).

<sup>6</sup> Silver, Shanti, "Estimating Psychiatric Bed Need in the United States," p. 2-4. Treatment Advocacy Center Office of Research and Public Affairs. January 2024. [https://www.tac.org/wp-content/uploads/2024/03/TAC\\_ORPA\\_ResearchSummary1.24.pdf](https://www.tac.org/wp-content/uploads/2024/03/TAC_ORPA_ResearchSummary1.24.pdf).